Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment

Area of Science:

• Oncology
• Hematology
• Cancer Biology

Background:

• The tumor microenvironment (TME) is a complex ecosystem of cells and non-cellular components influencing tumor behavior.
• Platelets, crucial for hemostasis, are increasingly recognized as key players in cancer progression and metastasis.
• Oral squamous cell carcinoma (OSCC) exhibits high rates of metastasis and poor prognosis, often linked to thrombocytosis and stromal factors.

Purpose of the Study:

• To review the multifaceted role of platelets within the tumor microenvironment, particularly in cancer promotion and progression.
• To investigate the specific interaction between platelets and OSCC via the C-type lectin-like receptor 2 (CLEC2) and podoplanin (PDPN) axis.
• To assess the therapeutic potential of targeting the CLEC2-PDPN axis for OSCC treatment, aiming to overcome limitations of traditional antiplatelet therapies.

Main Methods:

• Review of existing literature on platelet function in cancer, focusing on the TME.
• Analysis of the molecular interactions between platelets and cancer cells, specifically the CLEC2-PDPN pathway.
• Evaluation of clinical data correlating platelet counts and PDPN expression with OSCC metastasis and prognosis.

Main Results:

• Platelets contribute to cancer progression and metastasis by interacting with tumor cells within the TME.
• In OSCC, elevated platelet counts and PDPN expression are associated with increased lymph node metastasis and poorer outcomes.
• The platelet CLEC2-PDPN interaction facilitates cancer cell invasion and metastasis, highlighting it as a critical pathway.

Conclusions:

• Platelets are significant contributors to the TME and play a crucial role in OSCC progression and metastasis.
• The CLEC2-PDPN axis represents a specific and promising therapeutic target for inhibiting platelet-mediated OSCC metastasis.
• Targeting this axis offers a potential strategy for developing novel anti-cancer therapies with reduced bleeding risks compared to conventional antiplatelet drugs.